## **Amendments to the Claims:**

This listing of claims replaces all prior versions, and listings, of claims in the captioned application.

## **Listing of Claims:**

- 1. (Currently Amended) A pharmaceutical composition comprising a pharmaceutically acceptable carrier and, as active ingredients, an opioid analgesic and a therapeutically effective amount of a compound selected from the group consisting (+)-(B)-trans-4-[1-[3,5-bis(trifluoromethyl)benzoyl]-2-(phenylmethyl)-4-piperidinyl]-N-(2,6-dimethylphenyl)-1-piperazine acetamide in an amount effective to reduce the respiratory depression caused by the administration of an opioid analgesic; and pharmaceutically acceptable acid or base addition salts thereof, the stereochemically isomeric forms thereof, the N-oxide form thereof.
- 2. (Canceled)
- 3. (Canceled)
- 4. (Canceled)
- 5. (Canceled)
- 6. (Canceled)
- 7. (Canceled)
- 8. (Canceled)

- 9. (Withdrawn) A pharmaceutical composition according to claim 1 wherein, the pharmaceutical composition comprises a compound selected from the group consisting of :
- 4-[1-[3,5-bis(trifluoromethyl)benzoyl]-2-(phenylmethyl)-4-piperidinyl]-*N*-(2,6-dimethylphenyl)-1-piperazine acetamide;
- 4-[1-[3,5-bis(trifluoromethyl)benzoyl]-2-(phenylmethyl)-4-piperidinyl]-*N*-(1-phenylcyclohexyl)-1-piperazine acetamide;
- o 1-[3,5-bis(trifluoromethyl)benzoyl]-2-(phenylmethyl)-4-[4-[ -(1-pyrrolidinylcarbonyl)benzyl]-1-piperazinyl]piperidine;
- o 1-[3,5-bis(trifluoromethyl)benzoyl]-4-[4-[1-[(2-methyl-5-oxazolyl)methyl]-1*H*-benzimidazol-2-yl]-1-piperazinyl]-2-(phenylmethyl)piperidine;
- 4-[1-[3,5-bis(trifluoromethyl)benzoyl]-2-[(4-trifluoromethylphenyl)methyl]-4-piperidinyl]-*N*-(2,6-dimethylphenyl)-1-piperazine acetamide; and
- 4-[1-[3,5-bis(trifluoromethyl)benzoyl]-2-[(3,4-dichlorophenyl)methyl]-4-piperidinyl]-*N*-(2,6-dimethylphenyl)-1-piperazine acetamide.
- 10. (Currently Amended) A pharmaceutical composition according to claim 1 wherein, the pharmaceutical composition comprises
- ; and (+)-(B)-trans-4-[1-[3,5-bis(trifluoromethyl)benzoyl]-2-(phenylmethyl)-4-piperidinyl]-N-(2,6-dimethylphenyl)-1-piperazine acetamide (L)-malic acid (1:1).
- 11. (Previously Presented) A pharmaceutical composition according to claim 1 wherein, the pharmaceutical composition is formulated for simultaneous, separate or sequential use.
- 12. (Previously Presented) A pharmaceutical composition according to claim 1 wherein, the opioid analgesic is one or more compounds selected from the group consisting of alfentanil, buprenorphine, butorphanol, carfentanyl, codeine, diacetylmorphine, dihydrocodeine, fentanyl, hydrocodone, hydromorphone, levorphanol, lofentanyl, meperidine, methadone, morphine, nalbuphine, oxycodone, oxymorphone, pentazocine, propoxyphene, remifentanyl and sufentanyl; and derivatives and pharmaceutical acceptable salts thereof.

- 13. (Previously Presented) A pharmaceutical composition according to claim 12 wherein the opioid analysic is one or more compounds selected from the group consisting of oxycodone, codeine, morphine, fentanyl, buprenorphine, hydrocodone, hydromorphone and pharmaceutical acceptable salts and derivatives thereof.
- 14. (Previously Presented) A pharmaceutical composition according to claim 1 where, the pharmaceutical composition is in a form suitable to be orally administered.
- 15. (Canceled)
- 16. (Canceled)
- 17. (Canceled)
- 18. (Canceled)
- 19. (Canceled)
- 20. (Canceled)
- 21. (Withdrawn) A method for treating pain and/or nociception comprising administering to a person in need thereof an effective amount of a pharmaceutical composition according to claim 1.
- 22. (Withdrawn) A method for treating acute and chronic pain selected from the group consisting of inflammatory, post-operative, emergency room (ER), breakthrough, neuropathic and cancer pain comprising administering to one in need thereof an effective amount of a pharmaceutical composition according to claim 1.
- 23. (Withdrawn) A method for treating emesis in opioid-based treatments of pain comprising administering to one in need thereof an effective amount of a pharmaceutical composition

- according to claim 1.
- 24. (Withdrawn) A method for treating nausea and vomiting in opioid-based treatments of pain comprising administering to one in need thereof an effective amount of a pharmaceutical composition according to claim 23.
- 25. (Withdrawn) A method for treating respiratory depression in opioid-based treatments of pain comprising administering to one in need thereof an effective amount of an NK<sub>1</sub>-receptor antagonist selected from an NK<sub>1</sub>-receptor antagonist according to Formula (I), the pharmaceutically acceptable acid or base addition salts thereof, the stereochemically isomeric forms thereof, the *N*-oxide form thereof and prodrugs thereof.
- 26. (Withdrawn) A method for reducing and/or overcoming the tolerance observed with opioids in opioid-based treatments of pain comprising administering to one in need thereof an effective amount of an NK<sub>1</sub>-receptor antagonist selected from the group consisting of an NK<sub>1</sub>-receptor antagonist according to Formula (I), the pharmaceutically acceptable acid or base addition salts thereof, the stereochemically isomeric forms thereof, the *N*-oxide form thereof and prodrugs thereof.